## **Electronic Supplementary Information**

## Structural Characterisation of Amyloid-like Fibrils Formed by an Amyloidogenic Peptide Segment of β-Lactoglobulin

Vasantha Gowda <sup>a</sup>, Michal Biler <sup>b</sup>, Andrei Filippov <sup>cd</sup>, Malisa V. Mantonico <sup>a</sup>, Eirini Ornithopoulou <sup>a</sup>, Mathieu Linares <sup>bef</sup>, Oleg N. Antzutkin <sup>cg</sup>, Christofer Lendel \*<sup>a</sup>

<sup>a</sup> Dept. of Chemistry, KTH Royal Institute of Technology, Stockholm, Sweden.

<sup>b</sup> Dept. of Theoretical Chemistry, KTH Royal Institute of Technology, Stockholm, Sweden.

<sup>c</sup> Chemistry of Interfaces, Luleå University of Technology, Sweden.

<sup>d</sup> Dept. Medical and Biological Physics, Kazan State Medical University, 420012, Kazan, Russia.

<sup>e</sup> Laboratory of Organic Electronics and Group of Scientific visualization, ITN, Linköping University, 60174 Norrköping, Sweden

<sup>f</sup> Swedish e-Science Research Centre (SeRC), Linköping University, 60174 Norrköping, Sweden

<sup>g</sup> Dept. of Physics, University of Warwick, Coventry, UK.

\* Correspondence to C.L.: lendel@kth.se

	H <sup>N</sup>	Ηα	$\mathbf{H}^{\beta 1}$	<b>H</b> <sup>β2</sup>	$H^{\gamma 1}$	$H^{\gamma 2}$	H <sup>δ</sup>	$H^{\epsilon 1}$	H <sup>ε2</sup>
D	8.27	4.62	2.7	2.57					8.27
Ι	8.08	4.06	1.78		1.38	1.1	0.8		8.08
Q	8.34	4.21	1.96	1.88	2.25			7.17/7.08	8.34
Κ	8.21	4.22	1.64	1.55	1.25				8.21
V	8.05	4.03	1.97	-	0.88	0.81			8.05
Α	8.4	4.23	1.31						8.4
G	8.26	3.86							8.26
Т	7.84	4.2	3.97		0.96				7.84
W	8.08	4.54	3.12						8.08
Y	7.7	4.31	2.78	2.66					7.7

**Table S1.** <sup>1</sup>H {H<sub>2</sub>O+D<sub>2</sub>O (10%) solution} Chemical shift table for the  $\beta$ -LG<sub>11-20</sub> peptide are compared with random coil chemical shifts<sup>49</sup>.

**Table S2.** Backbone torsion angles  $\phi$  and  $\psi$  in  $\beta$ -LG<sub>11-20</sub> fibrils obtained using TALOS and MD simulations.

	Predicted	Predicted	MD simula	ted β-sheet	MD simulated β-sheet		
	TALOS $\phi$	TALOS $\psi$	structure	e (AB4)	structure (AA3)		
	angle in	angle in					
	fibrils	fibrils					
			$\phi$ angle	$\psi$ angle	$\phi$ angle	$\psi$ angle	
D	-	-	-80 ± 8	$125\pm12$	$-90 \pm 14$	$121 \pm 13$	
Ι	-122.218	123.814	$-113 \pm 12$	$126\pm16$	$-118 \pm 14$	$127 \pm 12$	
Q	-112.957	137.24	$-121 \pm 16$	$130\pm11$	$-113 \pm 13$	$130 \pm 10$	
Κ	-120.806	132.618	$-133 \pm 10$	$130\pm10$	$-124 \pm 11$	$121 \pm 16$	
V	-117.161	125.93	$-127 \pm 13$	$135\pm10$	-128 ± 9	$133 \pm 6$	
А	-112.417	126.779	$-144 \pm 13$	$141\pm22$	-137 ± 19	$134\pm27$	
G	-119.366	135.807	-111 ± 23	$113\pm24$	$-94 \pm 28$	$118\pm25$	
Т	-127.937	136.017	$-137 \pm 14$	$137\pm19$	$-125 \pm 16$	$120\pm18$	
W	-107.677	134.448	$-124 \pm 14$	$129\pm19$	-117 ± 16	$122\pm35$	
Y	-	-	$-113 \pm 14$	$102\pm26$	$-94 \pm 24$	$112 \pm 17$	

\* Data are extracted from the last 5 ns of relevant MD simulations with 500 points collected (10 ps/point) per each amino acid.



**Figure S1.** <sup>1</sup>H NMR spectrum of the  $\beta$ -LG<sub>11-20</sub> peptide in H<sub>2</sub>O+10% D<sub>2</sub>O solution, expanded regions: A) 6.6-10.1 ppm B) 0.5- 4.6 ppm.



**Figure S2.** A) <sup>13</sup>C (<sup>15</sup>N coupled) NMR spectrum of the uniformly <sup>13</sup>C/<sup>15</sup>N labelled (I and T residues)  $\beta$ -LG<sub>11-20</sub> peptide in H<sub>2</sub>O+10% D<sub>2</sub>O solution. **B**) <sup>13</sup>C (<sup>15</sup>N coupled) NMR spectrum of the uniformly <sup>13</sup>C/<sup>15</sup>N labelled (V, A, and G residues)  $\beta$ -LG<sub>11-20</sub> peptide in H<sub>2</sub>O+10% D<sub>2</sub>O solution.



**Figure S3. A)** <sup>13</sup>C CP-MAS NMR spectrum of monomeric unlabelled  $\beta$ -LG<sub>11-20</sub> peptide (20480 acquisitions, 2.5 s relaxation delay, and 1.5 ms contact time). **B)** <sup>13</sup>C CP-MAS NMR spectrum of lyophilised unlabelled  $\beta$ -LG<sub>11-20</sub> fibrils (40960 acquisitions, 2.5 s relaxation delay, and 1.5 ms contact time). **C)** <sup>13</sup>C CP-MAS NMR spectrum of fully hydrated unlabelled  $\beta$ -LG<sub>11-20</sub> fibrils (61440 acquisitions, 2.5 s relaxation delay, and 1.5 ms contact time).



**Figure S4 A)** <sup>13</sup>C CP-MAS NMR spectrum of the uniformly <sup>13</sup>C/<sup>15</sup>N labelled (V, A, and G residues)  $\beta$ -LG<sub>11-20</sub> peptide (1024 acquisitions, 2.5 s relaxation delay, and 1.5 ms contact time). **B)** <sup>13</sup>C-<sup>13</sup>C solid-state PDSD NMR spectra of non-fibrillar peptide-VAG (DIQK<u>VAG</u>TWY)



**Figure S5. A)**<sup>13</sup>C CP-MAS NMR spectrum of the uniformly <sup>13</sup>C/<sup>15</sup>N labelled (I and T residues)  $\beta$ -LG<sub>11-20</sub> peptide (1024 acquisitions, 2.5 s relaxation delay, and 1.5 ms contact time). **B)** <sup>13</sup>C-<sup>13</sup>C solid-state PDSD NMR spectra of non-fibrillar peptide-IT(D<u>I</u>QKVAG<u>T</u>WY)



**Figure S6. A)** Illustration of a steric zipper structure (from PDB ID 1YJP). **B)** The two faces of the  $\beta$ -LG<sub>11-20</sub> peptide in extended strand conformation. **C)** Potential packing of anti-parallel (top row) and parallel (bottom row)  $\beta$ -sheet in "steric zippers". The colours indicate the faces as shown in panel B.





**Figure S7.** Six different arrangements of 40 peptides, considered in our 30 ns long MD simulations, in the *anti-parallel* A-A, B-B and A-B, and the *parallel* A-A, B-B and A-B zipper mode packing. Tyrosine and tryptophan moieties are shown in green and gray, respectively, and the beta sheet structures are highlighted in yellow. The most stable arrangements, BB-aPZ and BB-PZ, have *ca* 50 more H-bonding interactions and keep stable configuration during the simulation time with respect to the  $\pi$ - $\pi$  stacking interactions.